GlassScriptPhysician profile
Ellen T Song
NPI 1528079589
$2,443.73
in general payments reported to CMS, 2019-2025
22 companies · $523 in 2025
The $523 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $14.34 · 2021: $508 · 2022: $166 · 2023: $310 · 2024: $587 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.49 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.38 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $460.36 | 2024-2025 | Airsupra |
| Abbvie INC. | $225.75 | 2021-2025 | Qulipta, Synthroid, Ubrelvy |
| Medtronic Vascular, INC. | $191.57 | 2019 | |
| Eisai INC. | $168.04 | 2021 | |
| Novo Nordisk INC | $134.04 | 2023-2025 | Wegovy |
| Allergan, INC. | $124.99 | 2021 | |
| Gilead Sciences, INC. | $107.79 | 2019 | |
| Impel Pharmaceuticals INC. | $89.11 | 2023 | Trudhesa |
| Amarin Pharma, INC. | $88.21 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $84.98 | 2022-2024 | Contrave, Nexletol |
| Exact Sciences Corporation | $56.79 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $49.42 | 2022 | |
| Amgen INC. | $41.30 | 2022-2024 | Otezla, Repatha |
| Alfasigma USA, INC. | $33.43 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.98 | 2025 | Kisunla |
| Biohaven Pharmaceuticals, INC. | $20.61 | 2021 | |
| Pfizer INC. | $18.93 | 2025 | |
| Axsome Therapeutics, INC. | $16.57 | 2025 | Symbravo |
| Supernus Pharmaceuticals, INC. | $15.31 | 2023 | Qelbree |
| Medtronic, INC. | $15.03 | 2024 | Minimed 780g |
| Genentech USA, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.